NO944932L - Hemming av trombin - Google Patents

Hemming av trombin

Info

Publication number: NO944932L
Authority: NO; Norway
Prior art keywords: chem; thrombin; inhibition; hexamethyleneamino; pyrrolidino
Prior art date: 1993-12-21

Application number

NO944932A

Other languages

English (en)

Other versions

NO944932D0 (no

NO313081B1 (no

Inventor

Daniel Jon Sall

Gerald Floyd Smith

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-12-21

Filing date

1994-12-19

Publication date

1995-06-22

1994-12-19 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1994-12-19 Publication of NO944932D0 publication Critical patent/NO944932D0/no

1995-06-22 Publication of NO944932L publication Critical patent/NO944932L/no

2002-08-12 Publication of NO313081B1 publication Critical patent/NO313081B1/no

Links

108090000190 Thrombin Proteins 0.000 title abstract 2
229960004072 thrombin Drugs 0.000 title abstract 2
230000005764 inhibitory process Effects 0.000 title 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
-1 hexamethyleneamino Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)

NO19944932A 1993-12-21 1994-12-19 Anvendelse av en forbindelse for fremstilling av et medikament som er nyttig i forbindelse med hemming av trombin NO313081B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/171,394 US5441965A (en)	1993-12-21	1993-12-21	Methods of inhibiting thrombin

Publications (3)

Publication Number	Publication Date
NO944932D0 NO944932D0 (no)	1994-12-19
NO944932L true NO944932L (no)	1995-06-22
NO313081B1 NO313081B1 (no)	2002-08-12

Family

ID=22623580

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19944932A NO313081B1 (no)	1993-12-21	1994-12-19	Anvendelse av en forbindelse for fremstilling av et medikament som er nyttig i forbindelse med hemming av trombin

Country Status (21)

Country	Link
US (3)	US5441965A (no)
EP (1)	EP0664126B1 (no)
JP (1)	JPH07223947A (no)
KR (1)	KR950016744A (no)
CN (1)	CN1078070C (no)
AT (1)	ATE150308T1 (no)
AU (1)	AU693822B2 (no)
CA (1)	CA2138493A1 (no)
CZ (1)	CZ287725B6 (no)
DE (1)	DE69402173T2 (no)
DK (1)	DK0664126T3 (no)
ES (1)	ES2102154T3 (no)
GR (1)	GR3023537T3 (no)
HU (1)	HU224915B1 (no)
IL (1)	IL112048A (no)
NO (1)	NO313081B1 (no)
NZ (1)	NZ270185A (no)
RU (1)	RU94045846A (no)
TW (1)	TW321601B (no)
UA (1)	UA29446C2 (no)
ZA (1)	ZA9410084B (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6515009B1 (en)	1991-09-27	2003-02-04	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en)	1993-01-28	1998-09-22	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en)	1993-05-13	2002-05-28	Neorx Corporation	Method to determine TGF-β
US6251920B1 (en)	1993-05-13	2001-06-26	Neorx Corporation	Prevention and treatment of cardiovascular pathologies
US5770609A (en)	1993-01-28	1998-06-23	Neorx Corporation	Prevention and treatment of cardiovascular pathologies
US6491938B2 (en)	1993-05-13	2002-12-10	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en)	1993-01-28	1997-01-21	Neorx Corporation	Method for identifying an agent which increases TGF-beta levels
CA2162586C (en)	1993-05-13	2006-01-03	David J. Grainger	Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5545641A (en) *	1994-10-20	1996-08-13	Eli Lilly And Company	Methods of inhibiting physiological conditions associated with an excess of bradykinin
US6562862B1 (en)	1994-10-20	2003-05-13	Eli Lilly And Company	Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5484808A (en) *	1995-02-09	1996-01-16	Eli Lilly And Company	Methods of inhibiting cell-cell adhesion
US5840747A (en) *	1995-06-07	1998-11-24	Eli Lilly And Company	Calcium channel antagonists
ATE377418T1 (de)	1995-06-07	2007-11-15	Poniard Pharmaceuticals Inc	Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen
US6545027B1 (en)	1995-06-07	2003-04-08	Eli Lilly And Company	Methods of modulating NF-kB transcription factor
ES2180702T3 (es) *	1995-06-07	2003-02-16	Lilly Co Eli	Tratamiento de patologias por la induccion del factor de transcripcion bef-1.
CA2236007A1 (en)	1995-10-31	1997-07-17	Gerald Floyd Smith	Antithrombotic diamines
IL120266A (en) *	1996-02-28	2005-05-17	Pfizer	Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) *	1996-02-28	2001-06-23	Pfizer	New therapeutic uses of estrogen agonists
US5811437A (en) *	1996-05-21	1998-09-22	Eli Lilly And Company	Methods of increasing nitric oxide synthesis
US5747509A (en) *	1996-06-03	1998-05-05	Schering Aktiengesellschaft	Method for lowering plasma levels of lipoprotein(a)
ZA982877B (en) *	1997-04-09	1999-10-04	Lilly Co Eli	Treatment of central nervous system disorders with selective estrogen receptor modulators.
US6025373A (en) *	1997-04-22	2000-02-15	Eli Lilly And Company	Methods for reducing fibrinogen
ATE268768T1 (de)	1997-04-30	2004-06-15	Lilly Co Eli	Antithrombosemittel
WO1998049161A1 (en)	1997-04-30	1998-11-05	Eli Lilly And Company	Antithrombotic agents
WO1998048794A1 (en)	1997-04-30	1998-11-05	Eli Lilly And Company	Antithrombotic agents
WO1998048804A1 (en)	1997-04-30	1998-11-05	Eli Lilly And Company	Antithrombotic agents
US6103740A (en) *	1997-08-21	2000-08-15	Eli Lilly And Company	Methods for lowering platelet counts
US6187777B1 (en)	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases
AU749751B2 (en) *	1998-04-08	2002-07-04	Eli Lilly And Company	Pulmonary and nasal delivery of raloxifene
FR2777784B1 (fr) *	1998-04-27	2004-03-19	Arepa	Composition pharmaceutique a base d'estrogene et de progesterone
US6284756B1 (en)	1998-04-30	2001-09-04	Eli Lilly And Company	Antithrombotic agents
US6288108B1 (en)	1998-06-16	2001-09-11	Eli Lilly And Company	Methods for increasing levels of acetylcholine
KR20010052891A (ko)	1998-06-16	2001-06-25	피터 지. 스트링거	아세틸콜린 수치를 상승시키는 방법
US6353003B1 (en)	1998-06-17	2002-03-05	Eli Lilly And Company	Method for reducing levels of homocysteine and C-reactive protein
DK0997460T3 (da) *	1998-10-28	2003-03-31	Lilly Co Eli	Benzothiophenforbindelser som antithrombotiske midler og mellemprodukter
ES2246234T3 (es)	1999-05-04	2006-02-16	Strakan International Limited	Glicosidos de androgenos y actividad androgenica de los mismos.
US6613083B2 (en)	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
JP3887588B2 (ja) *	2002-08-30	2007-02-28	株式会社リガク	Ｘ線回折による応力測定法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4133814A (en) *	1975-10-28	1979-01-09	Eli Lilly And Company	2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) *	1981-04-03	1983-11-29	Eli Lilly And Company	Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) *	1981-04-03	1983-04-19	Eli Lilly And Company	Synthesis of acylated benzothiophenes
US5075321A (en) *	1987-03-24	1991-12-24	University Of Pennsylvania	Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) *	1988-10-31	1995-03-07	Endorecherche Inc.	Anti-estrogenic compounds and compositions
JP3157882B2 (ja) *	1991-11-15	2001-04-16	帝国臓器製薬株式会社	新規なベンゾチオフエン誘導体

1993
- 1993-12-21 US US08/171,394 patent/US5441965A/en not_active Expired - Fee Related
1994
- 1994-12-19 UA UA94129200A patent/UA29446C2/uk unknown
- 1994-12-19 ES ES94309472T patent/ES2102154T3/es not_active Expired - Lifetime
- 1994-12-19 NZ NZ270185A patent/NZ270185A/en unknown
- 1994-12-19 ZA ZA9410084A patent/ZA9410084B/xx unknown
- 1994-12-19 AT AT94309472T patent/ATE150308T1/de not_active IP Right Cessation
- 1994-12-19 RU RU94045846/14A patent/RU94045846A/ru unknown
- 1994-12-19 EP EP94309472A patent/EP0664126B1/en not_active Expired - Lifetime
- 1994-12-19 CZ CZ19943226A patent/CZ287725B6/cs not_active IP Right Cessation
- 1994-12-19 CA CA002138493A patent/CA2138493A1/en not_active Abandoned
- 1994-12-19 CN CN94119741A patent/CN1078070C/zh not_active Expired - Fee Related
- 1994-12-19 DE DE69402173T patent/DE69402173T2/de not_active Expired - Fee Related
- 1994-12-19 IL IL11204894A patent/IL112048A/en not_active IP Right Cessation
- 1994-12-19 HU HU9403675A patent/HU224915B1/hu not_active IP Right Cessation
- 1994-12-19 NO NO19944932A patent/NO313081B1/no unknown
- 1994-12-19 AU AU81558/94A patent/AU693822B2/en not_active Ceased
- 1994-12-19 DK DK94309472.2T patent/DK0664126T3/da active
- 1994-12-19 KR KR1019940034935A patent/KR950016744A/ko not_active Ceased
- 1994-12-19 TW TW083111851A patent/TW321601B/zh active
- 1994-12-19 JP JP6314564A patent/JPH07223947A/ja active Pending
1995
- 1995-04-14 US US08/422,288 patent/US5508292A/en not_active Expired - Fee Related
- 1995-04-14 US US08/422,730 patent/US5688813A/en not_active Expired - Fee Related
1997
- 1997-05-23 GR GR970401187T patent/GR3023537T3/el unknown

Also Published As

Publication number	Publication date
UA29446C2 (uk)	2000-11-15
DE69402173D1 (de)	1997-04-24
HUT71344A (en)	1995-11-28
CA2138493A1 (en)	1995-06-22
DE69402173T2 (de)	1997-07-17
AU693822B2 (en)	1998-07-09
NO944932D0 (no)	1994-12-19
US5441965A (en)	1995-08-15
KR950016744A (ko)	1995-07-20
ES2102154T3 (es)	1997-07-16
NZ270185A (en)	1997-07-27
IL112048A (en)	1999-03-12
US5508292A (en)	1996-04-16
HU224915B1 (en)	2006-04-28
NO313081B1 (no)	2002-08-12
IL112048A0 (en)	1995-03-15
US5688813A (en)	1997-11-18
EP0664126B1 (en)	1997-03-19
HU9403675D0 (en)	1995-02-28
TW321601B (no)	1997-12-01
ATE150308T1 (de)	1997-04-15
GR3023537T3 (en)	1997-08-29
AU8155894A (en)	1995-06-29
CZ322694A3 (en)	1995-09-13
EP0664126A1 (en)	1995-07-26
RU94045846A (ru)	1996-10-20
CZ287725B6 (en)	2001-01-17
ZA9410084B (en)	1996-06-19
JPH07223947A (ja)	1995-08-22
CN1078070C (zh)	2002-01-23
DK0664126T3 (da)	1997-09-01
CN1107704A (zh)	1995-09-06

Publication	Publication Date	Title
NO944932D0 (no)	1994-12-19	Hemming av trombin
NO943879D0 (no)	1994-10-13	Hemming av endometriose
NO943878D0 (no)	1994-10-13	Hemming av uterinfibrose
DE69402165D1 (de)	1997-04-24	Hemmung von Seborrhoe und Akne
NO943875L (no)	1995-04-18	Hemming av angiogenese og angiogene sykdommer
NO943873L (no)	1995-04-18	Hemming av bruskdegradering
NO944930D0 (no)	1994-12-19	Hemming av dysfunksjonell uterin blödning
DE69427807D1 (de)	2001-08-30	Hemmung von Hirsutismus und Alopecia bei Frauen